The DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.
Historical overview of the interleukin-6 family cytokine
Open accessAbstract
Interleukin-6 (IL-6) has been identified as a 26-kD secreted protein that stimulates B cells to produce antibodies. Later, IL-6 was revealed to have various functions that overlap with other IL-6 family cytokines and use the common IL-6 signal transducer gp130. IL-6 stimulates cells through multiple pathways, using both membrane and soluble IL-6 receptors. As indicated by the expanding market for IL-6 inhibitors, it has become a primary therapeutic target among IL-6 family cytokines. Here, we revisit the discovery of IL-6; discuss insights regarding the roles of this family of cytokines; and highlight recent advances in our understanding of regulation of IL-6 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Receptor composition of IL-6 family cytokines. IL-6 family cytokines use gp130 to transduce their signals through gp130 homodimers or gp130-containing heterodimers. IL-6, IL-11, CNTF, CLCF1, and CLCF1/CLF require binding of their nonsignaling receptor to transduce signals. A new group of members (IL-27, IL-35, and IL-39) are heterodimeric cytokines: IL-27 consists of IL-27/p28 (IL-27α) and EBI3 (also known as IL-27β); in conformity to IL-12 containing IL-12p40 (IL-12α) and IL-12p35 (IL-12β), IL-23 (IL-23p19 [IL-23α] and IL-23p40 [IL-23β]), IL-35 (IL-23p40 and EBI3), and IL-39 (IL-23p19 and EBI3; Hunter, 2005; Ning-Wei, 2010; Wang et al., 2016a). These new members activate heterodimers of gp130. IL-6R exerts its biological effects via three different signaling modes. IL-6R expression is restricted to hepatocytes and several types of immune cells, whereas gp130 is ubiquitously expressed, reflecting the diverse roles of IL-6. In the classical mode of IL-6 signaling, the cytokine interacts with mIL-6R in cells that also express gp130 (Hunter and Jones, 2015). IL-6 also binds soluble IL-6R (sIL-6R), which is shed from cells following cleavage by ADAM metalloprotease 17 (ADAM17), and is also created by alternative mRNA splicing (Lust et al., 1992). The IL-6–sIL-6R complex binds to gp130, forming a dimer that initiates intracellular signaling, a process referred to as trans-signaling. Recently, a third mode of IL-6 signaling was identified: IL-6 trans-presentation (Heink et al., 2017). This mode is specific to dendritic cells, in which the IL-6–mIL-6R complex is presented to gp130 expressed on T cells to prime pathogenic Th17 cells. These alternative modes of IL-6 signaling contribute to multiple cellular processes.](https://figures.cochat.ai/paper-figures/0d0052256f4b4b9dbf5a3cb45efbedda/historical-overview-of-the-interleukin-6-family-cytokine-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The increased Tag+ T cell effector responses in sgBaat were also accompanied by an increase in both CD4+ T cells and natural killer cells and elevated proinflammatory cytokines [interleukin-12 (IL-12), tumor necrosis factor (TNF), IFN-γ, IL-15, IL-7] and decreased tumor-promoting cytokines such as IL-6, leukemia inhibitory factor, and IL-11 within the liver microenvironment (Fig. 2D and figs. S3,”
From Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139
Self-citationKishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Self-citationStructural design and molecular evolution of a cytokine receptor superfamily.
Bazan, J. F. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.6934 · Cited by 2,069
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R. S., & Vignali, D. A. A. (2007) · Nature · doi:10.1038/nature06306 · Cited by 2,066
Gauldie, J., Richards, C., Harnish, D., Lansdorp, P., & Baumann, H. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7251 · Cited by 1,635
Pflanz, S., Timans, J. C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., Hibbert, L., Churakova, T., Travis, M., Vaisberg, E., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00324-2 · Cited by 1,462
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Self-citation(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146
Cited by
COVID-19 is, in the end, an endothelial disease
Libby, P., & Lüscher, T. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa623 · Cited by 961
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 375
Self-citationInterleukin-6 in Rheumatoid Arthritis
Pandolfi, F., Franza, L., Carusi, V., Altamura, S., Andriollo, G., & Nucera, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155238 · Cited by 278
Baldini, C., Moriconi, F. R., Galimberti, S., Libby, P., & De Caterina, R. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab447 · Cited by 167
Metadata
- Authors
- Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T.
- Affiliations
- Immunology Frontier Research Center, The University of Osaka (JP)
- The University of Osaka (JP)
- Corresponding author
- Kishimoto, Tadamitsu
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-04-08
- Volume
- 217
- Issue
- 5
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7201933
- OpenAlex
- W3014527183
- Cited by
- 360
- References
- 105
- Citations by year
- 2026: 25 · 2025: 96 · 2024: 76 · 2023: 72 · 2022: 49 · 2021: 33 · 2020: 9
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-04-27)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (17K15722, 17K10002)
- Astellas Foundation for Research on Metabolic Disorders
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- interleukin-6, IL-6 family cytokines, gp130, IL-6 receptor, IL-6 signaling, IL-6 inhibitors, B cell antibody production
- MeSH terms
- Animals, Humans, Models, Biological, Mutation, Interleukin-6, Receptors, Interleukin-6, MicroRNAs, History, 20th Century, Genetic Pleiotropy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Historical overview of the interleukin-6 family cytokine. https://app.cochat.ai/papers/10.1084/jem.20190347
- The paper
- Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020). Historical overview of the interleukin-6 family cytokine. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20190347
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.